Skip to main content

Table 1 Patient characteristics

From: MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients

 

Patient

Gender

Age

Clinical stage

AC [cm]

Chemotherapy

CEA

CA 19-9

Type of surgery

Histology

Grade

L/V/P

cT

cN

ypT

ypN

TRG

Residual cancer cells Avg/Max %

Local relaps

Distant relaps

Responders

01

M

30

IIIA

12

Xel

N

N

LAR

A

1

0

1

1

1

0

2

1/5

0

0

02

F

62

IIIA

13

Xel

N

N

LAR

A

2

0

x

1

1

1

2

2,5/5

0

0

03

F

67

IIA

3,5

Xel

N

N

APR

A

2

0

3

0

1

0

2

7,5/15

0

0

04

M

43

IIIA

9

Xel

N

N

uLAR

A

1

0

2

1

0

0

1

0/0

0

0

05

M

40

IIIB

5

Xel

E

N

APR

A

2

0

3

1

3

1

2

1/5

0

0

06

M

73

IIA

6,5

Xel

N

E

uLAR

A

2

0

3

0

0

0

1

0/0

0

0

07

M

68

IIIC

6

Xel

E

E

APR

A

2

0

3

2

0

0

1

0/0

0

0

08

M

58

IIIB

13

Xel

N

N

APR

A

1

0

3

1

3

0

2

2,5/40

0

Y

09

M

68

IIA

4,5

5FU

N

N

APR

A

2

0

3

0

0

0

1

0/0

0

0

10

M

43

IIA

4

Xel

N

N

uLAR

MA

2

0

3

0

0

0

1

0/0

0

0

Non-responders

11

M

63

IIIB

7

Xel

E

N

uLAR

A

2

0

3

1

2

0

4

15/50

0

0

12

M

59

IIIB

9

Xel

E

N

LAR

A

2

0

3

1

3

0

4

40/60

0

0

13

M

45

IIIC

4

Xel

N

N

APR

A

2

1P

3

2

3

1

3

7,5/50

Y

Y

14

F

64

IIIC

11

Xel

N

N

LAR

A

2

0

3

2

2

0

4

50/70

0

0

15

F

60

IIIA

9

Xel

N

N

LAR

A

1

0

2

1

1

0

4

70/80

0

0

16

F

69

IIIC

8

Xel

N

N

LAR

A

1

0

3

2

3

1

4

25/70

0

0

17

M

32

IIIC

10

Xel

N

N

LAR

A

2

0

2

2

3

0

4

55/75

0

0

18

M

53

IIIC

4

Xel

N

N

APR

A

3

0

3

2

2

0

3

40/60

0

0

19

M

63

IV*

7

5FU

E

N

APR

MA

2

0

3

2

3

2

4

60/80

0

Y

20

F

52

IIA

8

Xel

N

N

LAR

A

2

0

3

0

2

1

3

60/70

0

0

  1. N – Normal; E – Elevated; LAR – Low Anterior Resection; uLAR – Ultra (extended) Low Anterior Resection; APR –Abdominoperineal Resection; A – Adenocarcinoma; MA – Mucinous Adenocarcinoma; L/V/P – Lymphatic/Vascular/Perineural Invasion; 1P – Positive Perineural Invasion; TRG – Tumor Regression Score according to Mandard et al. (10); CEA – Carcinoembryonic antigen; CA 19–9 – cancer antigen 19–9; Clinical stage – according to TNM /UICC cancer staging classification, 6th Edition (ref. 5); cT/cN – clinical staging of primary tumor (T) / regional lymphatic nodes (N); ypT/ypN – histopathological staging of primary tumor and regional lymphatic nodes after neoadjuvant treatment; Residual cancer cells (Avg/Max %) – a proportion of cancer cells in all paraffin embedded tisue slices of primary tumor histologicaly examined after neoadjuvant treatment: Average (%) / Maximum (%) of cancer cells presented in examined slices; Xel – Xeloda (capecitabine); 5FU – 5-fluorouracil; M – male; F – female; AC – distance between the anocutaneous line and distal (aboral) margin of the tumor in cm; Y – yes; * in such patient a radical metastasectomy of solitary liver metastasis was first performed, followed by neoadjuvantchemoradiotherapy for locally advanced rectal cancer.